The purpose of this research study is to further establish the diagnostic use of
magnetocardiography (MCG) in patients with hypertrophic cardiomyopathy (HCM). The use of
MCG has not been extensively studied in these patients. This pilot study will serve to
further characterize abnormalities found on MCG in comparison to patients without
hypertrophic cardiomyopathy. Additionally, the study will be used to understand whether MCG
has any additional diagnostic utility in offering clinicians insight on the patient's
disease state, thereby aiding in the development of treatment plans.
This research study is designed to test the effectiveness of the investigational use of
magnetocardiography in patients with hypertrophic cardiomyopathy. The device itself has
been approved by the U.S Food and Drug Administration (FDA).
Patients with hypertrophic cardiomyopathy (HCM) have a gene mutation that results in
excessive thickening of heart muscle. Due to this abnormality these patients often present
with voltage changes on electrocardiograms (ECG) suggestive of abnormal electrical
conduction. The use of magnetocardiography (MCG) in these patients has yet to be extensively
studied. Magnetocardiography (MCG) is a safe, non-invasive, and FDA approved technology that
can be used to detect weak magnetic fields generated by the heart. The goal of this pilot
study is to determine common MCG findings in patients with HCM, while establishing the role
that MCG has in the evaluation and treatment of these patients.
We will enroll a total of twenty patients identified to have hypertrophic cardiomyopathy by
cardiologists at our facility. As patients' enroll in the study, data will be collected
prospectively. We will continue to follow up on patients over the course of 1 year from the
date of their initial enrollment. Once a patient has been identified as a candidate for this
study, they will be instructed about the risks and benefits of undergoing participation.
Informed consent to participate in the study will be obtained for each patient.
We will obtain basic demographic information on our patients including sex, age, race,
weight, height, and other co-morbidities and cardiovascular risk factors including, but not
limited to family history of syncope, sudden cardiac death, chest pain, or shortness of
breath. Information in regards to symptoms experienced, onset of symptoms, previous and
current diagnostic workup included blood work and cardiac scans, and current/past treatments
will also be recorded. A list of medications will be recorded.
Prior to the MCG scan, the patient will be instructed to wear only non-metallic containing
clothing. Patients's will then be requested to lie still on a table for a duration of 6
minutes, while undergoing a magnetocardiography scan. In addition to the MCG, the patient's
blood pressure and a 12-lead electrocardiogram will be obtained. Most patients will also
have a complete 2D echocardiogram which will require the patient to lie down on a table
while an ultrasound probe is placed on the left side of the chest resulting in an image of
the heart on a computer screen. In addition to the above, if clinically indicated patients
may have blood draws taken at the discretion of their cardiologist. These blood draws may be
used to obtain lipid levels, cardiac biomarkers, and natriuretic peptide assays (used to
evaluate heart failure).
Once a patient has completed an initial assessment and scan, we will ask the patient to
return for follow up visits at 3 months and 1 year for repeat MCG. A 2D ECHO will be
obtained at 3 months if clinically indicated, and at 1 year. In addition, we are asking for
follow up scans if the patient presents with any cardiac symptoms such as chest pain,
shortness of breath, or fainting Follow up phone interview will occur at 6 months. We will
ask information regarding symptoms, treatments, hospital admissions, cardiologist visits,
and any subsequent diagnostic testing performed including ECGs, transthoracic echos,
transesophageal echos, exercise/chemical stress testing, angiograms, and cardiac
1. Any patient that is hemodynamically stable and is identified to have hypertrophic
cardiomyopathy based on prior symptoms, 2D ECHO findings, genetic testing, and/or ECG
2. Patients that have signed informed consent after understanding the risks and benefits
of participation. Individual age 16-17 with the consent and approval of a parent and
/or legal guardian.
1. Patients with prior history of myocardial infarction, CAD demonstrated by stress test
or angiogram, and/or CABG will be excluded from this study.
2. Any patient that has undergone invasive treatment at the time of enrollment including
procedures such as myomectomy and/or septal ablation. However, already enrolled
subjects who have these procedures post-enrollment into the study will be eligible
for future scans.
3. Patients encountering any significant symptoms, chest pain, or who are
4. Any patient with an ICD or pacemaker.
5. Patients who are underage and do not have the consent of a parent and/or legal